DIRS.INFO The most relevant business & tech news

☆ Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
▼ + stars: | 2024-05-07 | by ( Scott Olson | Getty Images | ) www.cnbc.com time to read: +10 min

Amgen is among the leaders of a pack of drugmakers racing to join the market with their own weight loss treatments. Amgen's drug, MariTide, is taken less frequently than Novo Nordisk's Wegovy and Eli Lilly's Zepbound, and may cause longer-lasting weight loss than the market leaders' injections. Novo Nordisk and Eli Lilly are also working on new weight loss drugs. The competition for a slice of the weight loss market has only grown more fierce in recent months. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: NOVO.B, Scott Olson, Eli Lilly, Nordisk's Wegovy, Eli Lilly's Zepbound, Amgen, William Blair, Matt Phipps, Bob Bradley, Boehringer Ingelheim, Phipps, Zepbound, Chris Schott, MariTide, Mario Tama, he's, Eli Lilly drugs, CagriSema, Eli Lilly’s, Brendan McDermid, Boehringer, Ingelheim, survodutide, Pascal Soriot, Christopher Furlong, dealmaking, David Denton Organizations: New, Halstead Pharmacy, Getty, Novo Nordisk, Nordisk's, William Blair & Company, CNBC, Therapeutics, AstraZeneca, Zealand Pharma, MariTide, Reuters, GLP, Pfizer, Eccogene Locations: Chicago , Illinois, Novo, Amgen, Thousand Oaks , California, New York City, U.S, Zealand, Macclesfield

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Roche’s late obesity punt offers wider market cure
▼ + stars: | 2023-12-04 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Arnd Wiegmann Acquire Licensing RightsLONDON, Dec 4 (Reuters Breakingviews) - Roche’s (ROG.S) foray into the prospective $100 billion obesity market can bring wider benefits. On Monday, the $224 billion Swiss pharma group said it had agreed to take over weight-loss drug developer Carmot Therapeutics for $2.7 billion. Market leader Novo Nordisk (NOVOb.CO) is already selling obesity drugs in the U.S. and parts of Europe. Still, Schinecker’s obesity bet could turn successful if it ends up undercutting obesity pioneers on prices. With over 1 billion people globally classed as seriously overweight, other drugmakers will follow Roche on the obesity bandwagon.

Persons: drugmaker Roche, Arnd, Eli Lilly’s, Thomas Schinecker, Eli Lilly, Eccogene, Roche, Aimee Donnellan, Neiman Marcus, Lisa Jucca, Oliver Taslic Organizations: REUTERS, Reuters, Swiss pharma, Carmot Therapeutics, Novo Nordisk, U.S . Food, Drug Administration, AstraZeneca, Novo, X, Saks, Thomson Locations: Basel, Switzerland, U.S, Europe, Hong Kong

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsZURICH, Dec 4 (Reuters) - Roche (ROG.S) agreed to take over obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk (NOVOb.CO) and Eli Lilly. After encouraging Phase I trial results, the drug is ready to be tested on humans in the second of three trial stages, Roche added. Among recent deals to acquire obesity drug development projects, AstraZeneca (AZN.L) last month agreed to pay up to $2 billion for the rights to an experimental pill from China's Eccogene. Roche will obtain access to Carmot's current R&D portfolio including all clinical and preclinical assets.

Persons: drugmaker Roche, Arnd, ROG.S, Eli Lilly, Swiss drugmaker, Roche, . New Roche, Thomas Schinecker, Ludwig Burger, Noel Illien, Rachel More, Louise Heavens Organizations: REUTERS, Rights, Carmot Therapeutics, Novo Nordisk, AstraZeneca, Pfizer, Thomson Locations: Basel, Switzerland, Swiss, ., Alzheimer's

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

☆ AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
▼ + stars: | 2023-11-10 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). Eli Lilly shares had their worst day of the year Thursday, falling 4.5% in the session to close at $591.32. AstraZeneca's encroachment on turf currently dominated by Eli Lilly and Danish rival Novo Nordisk (NVO) may have contributed to Thursday's declines. That approval, despite being widely expected, pushed Eli Lilly to an all-time closing high Wednesday, at $619.13 per share. Our desire to own Eli Lilly over Novo Nordisk hinges, in part, on our confidence in Eli Lilly's other treatment opportunities, such as in Alzheimer's.

Persons: Eli Lilly, Jim Cramer, Jim, Lilly's, Eli Lilly's tirzepatide, Zepbound, Novo's, Eli Lilly's, Eli Lilly's GLP, Dave Ricks, Lilly, Ricks, AstraZeneca's, ECC5004, retatrutide, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: AstraZeneca, Novo Nordisk, American Heart Association, Novo Nordisk's semaglutide, CNBC, Reuters, Citigroup Locations: Danish, GLP, North Carolina, Novo, Denmark, Zepbound, Alzheimer's

☆ There's a new entry into the weight loss drug boom. Here's the outlook for the stock
▼ + stars: | 2023-11-09 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

AstraZeneca is the latest player to enter the weight loss drug arena, a market which some analysts have forecasted could reach $100 billion by 2030 . The GLP-1 drug market is currently dominated by two players: Novo Nordisk , which sells Type 2 diabetes treatment Ozempic and weight loss medication Wegovy, and Eli Lilly , which sells Mounjaro as a treatment for Type 2 diabetes. Lilly just had the weight loss version of its drug, Zepbound , approved by the Food and Drug Administration. It's still early days for AstraZeneca's ECC5004 drug, which is being assessed in a U.S.-based phase 1 trial involving patients with Type 2 diabetes. He currently rates AstraZeneca stock as overweight.

Persons: Eccogene, Wegovy, Eli Lilly, Lilly, It's, Colin White, James Gordon, Morgan Stanley, Mark Purcell, AstraZeneca's Farxiga, Purcell, Michael Bloom, Christina Cheddar, Berk Organizations: AstraZeneca, Novo Nordisk, Food and Drug Administration, Centers for Disease Control, UBS, Wall Street, JPMorgan Locations: U.S

It also expects total revenue to increase by a mid single-digit percentage, compared with low-to-mid single-digit growth previously. For the third consecutive quarter, strong sales of AstraZeneca's blockbuster cancer treatments and healthy demand for its drugs in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy. The results add to a string of strong quarters for Britain's biggest company by market capitalisation - worth 159 billion pounds ($195 billion) - bolstered by a strong pipeline of drugs. It said that in the first nine months of 2023, nine medicines delivered more than $1 billion in revenue. Excluding sales of its COVID-19 products, third-quarter sales rose 12% to $2.96 billion in emerging markets on a constant currency basis.

Persons: Phil Noble, China's, Maggie Fick, Eva Mathews, Nivedita Bhattacharjee, Mark Potter Organizations: AstraZeneca, REUTERS, Britain's, Thomson Locations: Macclesfield, England, China, London, Swedish, Bengaluru

Search resuls for: "Eccogene"

8 mentions found